A private pharmaceutical company is in the process of developing a patented drug to treat Nocturia and is expected to be the first to market in the space. With the size of the market, revenue is expected to be $20 billion at 15 cents a dose. The drug is a low dose combination of ibuprofen…
A medical laboratory has developed an add-on to any standard minimally invasive surgical (MIS) tool allowing surgeons and surgical residents to receive real time force feedback. The add-on accurately measures the force being exerted on the tissue from the instrument’s tip and relays the information wirelessly via visual force-feedback. This feedback reduces unsafe force levels…
A Canadian based oncology biotechnology company is developing targeted treatments for patients who need them the most. The leading compound SP-2577 represents a potential paradigm shift in the treatment of cancer. They are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where there are no targeted therapies currently available. Moreover,…
An American privately-held company, it is a pioneer in the field of biosimilars and complex generic drugs. Since 1995, they have been a leading developer of high-quality biosimilar therapeutics. Our technological expertise and infrastructure enable full-cycle product development, commercial manufacturing and product commercialization. Improving patient benefit by expanding access to biologic drugs This company…